Entos Pharmaceuticals Inc.
$62,000,000.00 CAD
- Program
- SIF Stream2- Growth
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- February 13, 2025 – June 1, 2047
- Reference
- ic:033-2024-2025-Q4-819748
Published purpose
This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Alberta for the production of novel genetic medicines.
In plain English AI-generated
This project funds the establishment of an R&D centre and a commercial-scale GMP manufacturing facility in Edmonton, Alberta, for producing novel genetic medicines.
Category: Research Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.